Stem definition | Drug id | CAS RN |
---|---|---|
4520 | 298-14-6 |
Molecule | Description |
---|---|
Synonyms:
|
Approved by EMA in combination with potassium citrate.
|
Dose | Unit | Route |
---|---|---|
4 | g | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
April 30, 2021 | EMA | Advicenne S.A. | |
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 31.15 | 30.53 | 24 | 637 | 263391 | 63224970 |
Disease progression | 31.10 | 30.53 | 18 | 643 | 122740 | 63365621 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Burkholderia test positive | 50.44 | 39.07 | 8 | 180 | 1015 | 34955728 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Disease progression | 33.41 | 29.59 | 21 | 727 | 184341 | 79559299 |
None
Source | Code | Description |
---|---|---|
ATC | A12BA04 | ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS POTASSIUM Potassium |
CHEBI has role | CHEBI:35225 | buffer compounds |
CHEBI has role | CHEBI:64049 | pH control agents |
CHEBI has role | CHEBI:77971 | food raising agent |
CHEBI has role | CHEBI:86328 | anti-fungal agrichemical |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Peptic ulcer | indication | 13200003 | DOID:750 |
Heartburn | indication | 16331000 | |
Hypokalemia | indication | 43339004 | |
Indigestion | indication | 162031009 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Hypokalemia Prevention | indication | ||
Gastric Hypersecretory Conditions | indication | ||
Hiatal Hernia with Reflux Esophagitis | indication | ||
Multiple endocrine adenomas | off-label use | 60549007 | |
Systemic mast cell disease | off-label use | 397016004 | DOID:349 |
Stress-Related GI Mucosal Bleeding Prevention | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Hyperkalemia | contraindication | 14140009 | |
Complete atrioventricular block | contraindication | 27885002 | |
Gastrointestinal ulcer | contraindication | 40845000 | |
Chronic heart failure | contraindication | 48447003 | |
Congenital myotonia, autosomal dominant form | contraindication | 57938005 | |
Acute nephropathy | contraindication | 58574008 | |
Hyperchloremia | contraindication | 74450001 | |
Third degree burn injury | contraindication | 80247002 | |
Oliguria | contraindication | 83128009 | |
Hyporeninemic hypoaldosteronism | contraindication | 236464008 | |
Edema | contraindication | 267038008 | |
Familial hyperkalemic periodic paralysis | contraindication | 304737009 | DOID:14451 |
Azotemia | contraindication | 445009001 | |
Severe dehydration | contraindication | 450316000 |
None
None
None
None
None
None
ID | Source |
---|---|
D02077 | KEGG_DRUG |
4017518 | VUID |
N0000145903 | NUI |
4017518 | VANDF |
CHEBI:81862 | CHEBI |
CHEMBL2106975 | ChEMBL_ID |
C026329 | MESH_SUPPLEMENTAL_RECORD_UI |
DB11098 | DRUGBANK_ID |
34296 | RXNORM |
1810 | MMSL |
5324 | MMSL |
d03600 | MMSL |
000745 | NDDF |
000765 | NDDF |
419980002 | SNOMEDCT_US |
77849004 | SNOMEDCT_US |
C0071751 | UMLSCUI |
516893 | PUBCHEM_CID |
HM5Z15LEBN | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
KLOR-Con/EF | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-5326 | TABLET, EFFERVESCENT | 978 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
Alka-Seltzer Gold | HUMAN OTC DRUG LABEL | 3 | 0280-4100 | TABLET, EFFERVESCENT | 344 mg | ORAL | OTC monograph final | 16 sections |
Alka-Seltzer Gold | HUMAN OTC DRUG LABEL | 3 | 0280-4100 | TABLET, EFFERVESCENT | 344 mg | ORAL | OTC monograph final | 16 sections |
K-EFFERVESCENT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4170 | TABLET, EFFERVESCENT | 25 meq | ORAL | unapproved drug other | 16 sections |
TowerX Effervescent Potassium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50201-2400 | TABLET, EFFERVESCENT | 25 meq | ORAL | unapproved drug other | 17 sections |
Effer-K Orange | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-001 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
Effer-K Lemon Citrus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-005 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
Effer-K Cherry Berry | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-006 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
Effer-K Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-007 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
Effer-K 20 mEq Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-011 | TABLET, EFFERVESCENT | 782 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
Effer-K 20 mEq Orange Cream | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-012 | TABLET, EFFERVESCENT | 782 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
Effer-K 10 mEq Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-013 | TABLET, EFFERVESCENT | 391 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
Effer-K 10 mEq Cherry Vanilla | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-014 | TABLET, EFFERVESCENT | 391 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
Pleo Alkala Antacid | HUMAN OTC DRUG LABEL | 3 | 60681-6001 | POWDER | 117 g | ORAL | OTC monograph final | 26 sections |
Relief OTC antacid | HUMAN OTC DRUG LABEL | 3 | 69016-001 | LIQUID | 905 mg | ORAL | OTC monograph final | 14 sections |